We have upgraded Myriad Genetics (MYGN) to Neutral from Underperform based on the impressive performance of its molecular diagnostics business. Effective July 1, 2009, the company spun off its therapeutics business to focus on molecular diagnostics.

We believe that the de-risking strategy to separate the profitable predictive medicine business from the higher risk drug development business will create better value for shareholders. Each company will be able to pursue its long-term strategic initiatives, maximize its core technology strengths, seek new product opportunities, have a capital structure appropriate for its financial profile, and compete more effectively in its respective markets.

Sales of Myriad Genetics’ molecular diagnostic products continued to grow impressively in the first quarter of fiscal 2010. Sales came in at $85.1 million, versus $70.0 million for the same period in the prior year, reflecting a 21.6% increase. We remain optimistic about the predictive medicine market and believe it will keep recording double-digit growth in the coming years.

The impressive portfolio of molecular diagnostic products boasted by Myriad Genetics has also resulted in the stock being upgraded. Myriad Genetics currently has seven predictive medicine products on the market. Myriad’s products are vital to the healthcare management of patients with cancer or a family history of cancer. They have the potential to be life savers and save healthcare costs.

Based on the above reasons, we have upgraded Myriad Genetics to Neutral with a price target of $25.50. Our target price is based on 16.8x our 2010 EPS estimate of $1.52.

Zacks Investment Research

1. (MYGN) Myriad Genetics – Bear of the DayMyriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share,...
2. (MYGN) Myriad Genetics Inc Misses Forecasts by a PennyMyriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny...
3. (MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents EstimateYesterday, Myriad Genetics Inc. (MYGN) reported fourth quarter earnings of 37 cents per share from...
4. (MYGN) Myriad Genetics, Inc. – Momentum – Zacks Rank BuyMyriad Genetics, Inc. (MYGN) continues to head higher after the company reported strong earnings on...
5. (MYGN) Myriad Genetics – Revenues increased 58%, on a year-over-year basisMyriad Genetics, Inc. (MYGN) has just reported a fantastic quarter and shares have responded. Analysts...
6. (MYGN) Myriad Genetics – Revenue increased 53% from last yearMyriad Genetics, Inc.’s (MYGN) share price continues to advance after the company reported a great...

Search Posts by Tag: MYGN | Myriad Genetics Inc. | Diagnostic Substances | Healthcare

RSS Feeds by Tag: MYGN | Myriad Genetics Inc. | Diagnostic Substances | Healthcare |

Other Posts by: vitalstocks | RSS Feed for this author